Guided by our uncompromising commitment to patients, we are committed to going the distance in cystic fibrosis. Learn more about what we're focused on as we continue our journey.
We are relentless in our quest to improve the lives of people living with serious diseases. Thanks to the dedication of teams led by Paul Negulescu, our medicines have profoundly impacted the cystic fibrosis community, earning recognition such as the prestigious Canada Gairdner International Award.
The Vertex Foundation Scholarship helps eligible people with cystic fibrosis and their families in the United States and Canada pursue higher education degrees. We award recipients $5,000 USD/CAD toward the 2025-2026 academic year.
Vertex is committed to working alongside the CF community on this journey to support those living with CF.
Learn how we explore the daily lives of those living with debilitating disease to help inform our mission.
Learn how our teams utilize real-world research to understand the lived impacts of sickle cell disease and beta thalassemia.
Chief Scientific Officer David Altshuler reflects on the history of innovation that serves as inspiration as we pursue a brighter future for people living with type 1 diabetes.
Chief Human Resources Officer Stephanie Franklin discusses Vertex’s inclusive benefits and how they are helping Vertexians.
Dr. Ogo Egbuna leads clinical development for our genetic kidney disease programs. Learn more about APOL1-mediated kidney disease from a nephrologist’s perspective.
We’re committed to carefully managing our environmental footprint. Learn more from Charlie Wagner, our Chief Financial Officer, about the progress we’re making to conserve water and to reduce our greenhouse gas emissions.
Sustainability is both a priority and a team effort. Learn more about how we're dedicated to being responsible global citizens from Executive Director Katharine Jensen.
We’ve been working with the beta thalassemia community since the inception of our research program in 2015. Learn more about our efforts and commitments around the globe.
Diana Cruz Solash, Vice President of Talent and ID&E, shares game-changing insights from our seventh annual ID&E Week.
Individuals living with severe sickle cell disease report higher exposure to health care prejudice, according to new research by our Health Economics and Outcomes Research (HEOR) team.
Vertex is committed to the sickle cell disease community. Beyond our science, it’s about showing up and locking arms with the community to work together toward meaningful change.
Though they come from different backgrounds, our scientists share a passion and dedication to pushing our science forward. Meet the people driving innovation at Vertex.
Understanding the real-life impacts of managing SCD and TDT.
Chief Human Resources Officer Stephanie Franklin discusses our unique culture at Vertex and how we bring our culture to life.
Vice President of Clinical Development Dr. Ogo Egbuna shares why it’s important to raise awareness about APOL1-mediated kidney disease (AMKD).
Learn why the Vertex Pharmaceuticals approach to career growth is unique from Chief Human Resources Officer Stephanie Franklin.
ID&E Week is our annual opportunity to press pause and listen, learn and reflect. This year’s theme, “Catalysts for Change,” was also a call to action for Vertexians to ignite actionable change. Hear from Vice President Diana Cruz Solash on key takeaways from our sixth annual ID&E Week.
The Sickle Cell Disease Partnership is a multistakeholder coalition, launched in June, which works to improve care and access for people living with sickle cell disease. Here, Chief Patient Officer Amit Sachdev discusses the partnership, its goals and the reasons it was founded.
